{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-075317","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.292244+00:00","generated_at":"2026-06-01T03:38:02.070849+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MindMed reaches alignment with FDA on Phase 3 plan for MM120 in GAD","bullets":["Constructive End-of-Phase 2 meeting with FDA; aligned on Phase 3 requirements for MM120 (LSD D-tartrate) in generalized anxiety disorder.","Phase 3 program initiation remains on schedule for second half of 2024.","Phase 2b MMED008 trial results: MM120 100 µg cohort showed 65% clinical response rate and 48% remission rate on HAM-A at Week 12.","Last new FDA approval for GAD was in 2007; no robust treatment options have emerged since."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-075317","json":"https://secwatch.observer/filing/0000950170-24-075317.json","markdown":"https://secwatch.observer/filing/0000950170-24-075317.md","text":"https://secwatch.observer/filing/0000950170-24-075317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024075317/0000950170-24-075317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024075317/mnmd-20240620.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:38:02.070849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}